These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7730231)

  • 61. Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
    Sato A; Kitazawa H; Hayakawa H; Chida K; Iwata M
    J Antimicrob Chemother; 1997 Feb; 39(2):217-22. PubMed ID: 9069542
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current status of antibiotic treatment for Mycoplasma pneumoniae infections.
    McCracken GH
    Pediatr Infect Dis; 1986; 5(1):167-71. PubMed ID: 3080736
    [No Abstract]   [Full Text] [Related]  

  • 63. Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans.
    Takashima I; Ngoma M; Hashimoto N
    Antimicrob Agents Chemother; 1993 Apr; 37(4):901-2. PubMed ID: 8388204
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A new antimicrobial quinolone (AM-1155) analysed in hair as an index of drug exposure and as a time-marker.
    Uematsu T; Kusajima H; Umemura K; Ishida R; Ohkubo H; Nakashima M
    J Pharm Pharmacol; 1993 Nov; 45(11):1012-4. PubMed ID: 7908031
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Parameters of Mycoplasma pneumoniae infection in Syrian hamsters.
    Barile MF; Chandler DK; Yoshida H; Grabowski MW; Harasawa R; Razin S
    Infect Immun; 1988 Sep; 56(9):2443-9. PubMed ID: 3137169
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization and pathogenicity of hemolysis mutants of Mycoplasma pneumoniae.
    Yayoshi M; Araake M; Hayatsu E; Kawakubo Y; Yoshioka M
    Microbiol Immunol; 1984; 28(3):303-10. PubMed ID: 6429484
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effects of the combination of new quinolones and a nonsteroidal anti-inflammatory drug, fenbufen, on the EEG of rabbits].
    Suzuki T; Hara Y; Tamagawa M; Kakizaki K; Murayama S
    Nihon Yakurigaku Zasshi; 1992 Jan; 99(1):45-54. PubMed ID: 1313778
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.
    Yoshimatsu Y; Ishizaka T; Chiba K; Mori K
    Exp Anim; 2018 May; 67(2):281-290. PubMed ID: 29311442
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.
    Kawai Y; Miyashita N; Kubo M; Akaike H; Kato A; Nishizawa Y; Saito A; Kondo E; Teranishi H; Ogita S; Tanaka T; Kawasaki K; Nakano T; Terada K; Ouchi K
    Antimicrob Agents Chemother; 2013 May; 57(5):2252-8. PubMed ID: 23459497
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gatifloxacin.
    Perry CM; Barman Balfour JA; Lamb HM
    Drugs; 1999 Oct; 58(4):683-96; discussion 697-8. PubMed ID: 10551438
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
    Schaumann R; Ackermann G; Pless B; Claros MC; Rodloff AC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2783-6. PubMed ID: 10543764
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
    Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M; Ishida K; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Ikejima H; Yamamoto H; Ishida K; Kaku M; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):148-50. PubMed ID: 11810555
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
    Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    J Antimicrob Chemother; 1994 Dec; 34(6):875-83. PubMed ID: 7730231
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.